Retatrutide vs Tirzepatide: What Separates the Two Compounds

The two numbers everyone quotes are 24.2 percent and 20.9 percent. Retatrutide ahead, tirzepatide behind, comparison settled.

Those numbers are real and both come from published trials. They also cannot be compared to each other, for reasons that take about a paragraph to explain and that almost no page ranking for this term bothers with. One came from a 48-week phase 2 study of 338 people. The other came from a 72-week phase 3 study of roughly 2,500. No trial has ever tested the two compounds against each other. What follows is what each one actually is, what its own trial reported, and how to read the gap between them honestly.

Retatrutide vs tirzepatide at a glance

The last row is the one doing the most work, and it is the row that gets left out. Everything above it describes two compounds measured separately, by the same company, under conditions chosen to answer two different questions at two different stages of development.

What is retatrutide, and how the triple agonist works

Retatrutide, developed under the code LY3437943, is a single peptide engineered to activate three receptors at once: GLP-1, GIP, and glucagon.

The first two are familiar territory. GLP-1 and GIP are incretin hormones, released by the gut after eating, and activating their receptors reduces appetite, slows gastric emptying, and improves insulin response. That is the mechanism behind the entire current generation of these compounds.

Glucagon is the addition, and it is counterintuitive. Glucagon’s textbook job is raising blood sugar, which sounds like the opposite of what you would want. But it also increases energy expenditure and mobilizes fat from the liver, and the design bet behind retatrutide is that adding controlled glucagon activity on top of strong incretin activity produces net benefit: the incretin arms handle intake and glucose control, the glucagon arm raises output.

Whether that bet holds at scale is what phase 3 exists to determine. The phase 2 results published in the New England Journal of Medicine in 2023 were striking enough to make retatrutide the most-watched compound in the category, and striking phase 2 results have a long history of shrinking in phase 3.

What tirzepatide is and what it is approved for

Tirzepatide is a 39-amino-acid peptide activating GLP-1 and GIP receptors. It reached the market first and it is the reference point everything else in the class is measured against.

The FDA approved it as Mounjaro for type 2 diabetes in 2022, then as Zepbound for chronic weight management in 2023. Behind those approvals sits a large trial program: SURPASS for diabetes endpoints, SURMOUNT for obesity. SURMOUNT-1, the trial producing the 20.9 percent figure, ran 72 weeks across roughly 2,500 participants and was published in the New England Journal of Medicine in 2022.

Later work extended into other territory, including a trial in obstructive sleep apnea that led to an additional approval. That breadth of evidence is the practical difference between the two compounds, and it does not show up in a single percentage.

Retatrutide vs tirzepatide: why the headline numbers do not compare

Four differences make the 24.2 against 20.9 comparison unreliable, and any one of them alone would be enough to complicate it.

Trial phase. Phase 2 studies are smaller, shorter, and run in more tightly selected populations. Effect sizes routinely shrink when a compound moves to phase 3 and meets a broader group of people under stricter conditions. This is so common it has a name in the literature, and it is the single biggest reason to hold the retatrutide figure loosely.

Duration. Forty-eight weeks against seventy-two. Weight loss curves in this class had not fully plateaued at either point, so the two numbers are snapshots taken at different moments on different curves.

Population size and composition. 338 participants against roughly 2,500. The smaller the trial, the wider the confidence interval around any result.

No shared control. Both were placebo-controlled, but against different placebo groups in different studies with different baseline characteristics. Cross-trial comparison is an accepted way to generate a hypothesis and a poor way to settle one.

The defensible statement is that retatrutide’s early data is promising and its phase 3 program will produce the number that matters. Anything more confident than that is reading a press release as a result.

What phase 3 has to answer about retatrutide

The phase 3 program runs under the TRIUMPH name across several trials, and it is worth knowing what it is actually testing, because that is what will replace the number everyone currently quotes.

The obvious question is whether 24.2 percent survives contact with a larger and less selected population. The less obvious ones matter more.

Glucagon receptor activity has no accumulated long-term safety record in this context. The heart rate signal from phase 2 needs a larger dataset behind it. Glucagon raises hepatic glucose output, which is exactly the process that metabolic medicine usually tries to suppress, so demonstrating that the incretin arms reliably outweigh it across a broad population is a genuine requirement rather than a formality. And the compound is being studied in liver fat and in knee osteoarthritis alongside the obesity endpoints, which will show whether the glucagon component delivers anything the dual agonists do not.

People search constantly for when retatrutide will be available. There is no announced approval date, and phase 3 programs of this size typically report over several years rather than months. Anything quoting a specific launch date is guessing.

Retatrutide vs semaglutide: the third comparison

Semaglutide is the other compound people search alongside these two, and it sits one step further back mechanistically.

Semaglutide is a single-receptor compound, GLP-1 only, at 31 amino acids. Its STEP 1 trial reported roughly 15 percent mean weight reduction over 68 weeks. The progression across the three compounds tracks the number of receptors involved: one receptor around 15 percent, two around 21 percent, three around 24 percent in early data.

That pattern is tidy enough to be worth a note of caution. Three compounds from overlapping development programs, measured in separate trials, producing a neat ascending line is the kind of result that invites more confidence than the underlying comparison supports. The mechanism is plausible and the trials were not designed to demonstrate that progression.

What the retatrutide and tirzepatide trials reported on side effects

Both compounds produced gastrointestinal effects as the dominant finding: nausea, vomiting, diarrhea, and constipation, generally dose-dependent and heaviest during dose escalation. These were the main driver of participants leaving both trials.

Retatrutide’s phase 2 additionally reported dose-dependent increases in heart rate, which received attention because it is a plausible consequence of glucagon receptor activity and because cardiovascular signals in a metabolic drug are taken seriously. Whether it persists or resolves over longer exposure is a phase 3 question.

The retatrutide trial also reported hair thinning among adverse events, notably more often in female participants than male. It is not a large finding and it has not been characterized further, but it is a real entry in a published trial rather than an internet rumor, and it is one of the few sex-differentiated signals anywhere in this literature.

Body composition is the shared question neither trial resolved. A meaningful share of the weight lost on compounds in this class is lean mass rather than fat, which the headline percentage does not distinguish. That matters differently depending on where someone is starting from and how old they are, and it is a live enough concern that the next generation of trials in this field is being designed with muscle preservation as an explicit endpoint.

Neither compound is appropriate to discuss in terms of what someone should do about any of this. These are trial observations, and the material sold for research use is not the approved product those trials studied.

Retatrutide vs tirzepatide for women: what the trial populations showed

Both trials enrolled majority-female populations, which makes this class unusual in a field that has historically run on male subjects. SURMOUNT-1 was roughly two-thirds women.

Majority enrollment is not the same as analysis by sex, though. Neither program was designed to compare response between men and women, and neither stratified by hormonal status, which means the results average across premenopausal, perimenopausal, and postmenopausal participants as a single group.

That matters more here than it would for most compounds, because body composition and fat distribution shift measurably across the menopausal transition, independent of total weight. A compound evaluated on percentage of body weight lost is being measured against a baseline that is itself changing for a substantial share of the participants. The hair thinning signal is the one place where a sex difference surfaced at all, and it surfaced without explanation.

Where to source retatrutide and tirzepatide

Both are sold as research compounds and, in tirzepatide’s case, also as an approved pharmaceutical under two brand names. Those are not interchangeable. Research material is supplied for laboratory use and is not the approved product regardless of the compound name.

For research material the certificate of analysis carries the entire verification burden: an independent laboratory named on the document with no ownership relationship to the vendor, a batch number matching your vial, purity by HPLC, identity by mass spectrometry. Identity confirmation is not optional in this class, since these compounds are structurally similar enough that mislabeling would not be visible on inspection.

Healio publishes every batch certificate openly at the research page, before purchase rather than on request afterward. Retatrutide and tirzepatide both sit in the weight loss peptide collection. Both ship lyophilized, and the reconstitution guide covers solvent choice, concentration, and how long a reconstituted vial stays stable.

Retatrutide vs tirzepatide: frequently asked questions

Is retatrutide better than tirzepatide?

No published trial has compared them directly, so the question cannot be answered from the current evidence. Retatrutide reported a larger figure in a smaller, shorter phase 2 study; tirzepatide reported its figure in a much larger phase 3 program and holds FDA approval. Those are different classes of evidence, not different scores on one test.

Is retatrutide FDA approved?

No. Retatrutide remains in phase 3 clinical trials and has no FDA approval for any indication. Tirzepatide is approved, as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Any retatrutide sold today is research material rather than an approved medicine.

How does retatrutide work?

It activates three receptors from a single molecule: GLP-1 and GIP, which reduce appetite and slow gastric emptying, plus glucagon, which increases energy expenditure and mobilizes liver fat. The glucagon component is what separates it from tirzepatide and is the part with the least accumulated safety data.

What is the difference between retatrutide and semaglutide?

Semaglutide activates one receptor, GLP-1. Retatrutide activates three. Semaglutide is approved and has years of accumulated use behind it; retatrutide is investigational. The wider explainer covers how the whole incretin group fits together.

Does retatrutide cause hair loss?

Hair thinning was recorded among adverse events in the phase 2 trial, reported more frequently in female than male participants. It was not a primary endpoint and has not been characterized beyond that, so the finding is real but preliminary. Larger phase 3 data will show whether it holds.

Related reading

• What Are Peptides for Weight Loss: the three mechanism groups, sorted out
• Peptides for Weight Loss for Women: what the trials covered, and what they averaged over
• Sermorelin vs Tesamorelin: the growth hormone route to the same goal

Research use only. Every compound referenced on this page is supplied strictly for laboratory research. Nothing here is dosing guidance, and you will not find administration instructions anywhere on this site. These materials are not for human consumption, have not been evaluated by the FDA, and nothing here is medical advice. Consult a qualified healthcare professional for questions about your own health.